INDEX

S.NO CONTENT PAGE NO

1 COMPANY OVERVIEW 3
2 PRODUCT OVERVIEW 6
3 FACTORS AFFECTING 8
SUPPLY
4 FACTORS AFFECTING 10
DEMAND
5 MARKET SURVEY 12
6 RESPONSE OF CONSUMER 13
7 OBSERVVATION 14
8 DEMAND SCHEDULE 15
9 TYPE OF COMPETITION 16
10 FORM OF MARKET 17
STRUCTURE
11 SHORT RUN EQUILIBRIUM 18
12 LONG RUN EQUILIBRIUM 19
13 LEVEL OF BARRIERS 20
14 AFFECT ON PRICE 22
STRATEGY
15 FINANCIAL STATEMENT 23
16 CSR 29
17 BIBLIOGRAPHY 34
Company Overview

Date of Establishment 1983

Revenue 580.952 ( USD in Millions )

Market Cap 161393.894597 ( Rs. in

Millions )

BnCorporate Address 159 C S T

Road,KalinaSantacruz
(East), Mumbai-400098,
Maharashtra
www.lupinworld.com

Management Details Chairperson - DeshBandhu

Gupta
MD - Kamal K Sharma
Directors - D K Contractor,
DeshBandhu Gupta, K U
Mada, K V Kamath, K V
Kamoth, Kamal K Sharma,
M D Gupta, Marc
Desaedeleer, Nilesh Gupta,
 R A Shah, R V Satam,
Richard Zahn, Sunil Nair,
Vijay Kelkar, Vinita Gupta

Business
operationBackground

Pharmaceuticals & Drugs Lupin is a transnational

company engaged in development of APIs, generic
and branded formulations.
It is the largest manufacturer of Tuberculosis drugs in
the world. It has onshore and offshore presence of its
products in 70 countries.
Its manufacturing unit is located in Goa, Tarapur,
Ankleshwar, Jammu, Mandideep, Indore,
 Key excutive
S.No Name Designation
1 DeshBandhu Gupta Chairman
3 Kamal K Sharma Managing Director
2 R V Satam Company Secretary
4 D K Contractor Director
5 Vinita Gupta Director
6 K U Mada Director
7 R A Shah Director
8 M D Gupta Executive Director
9 Nilesh Gupta Executive Director
10 Vijay Kelkar Additional Director
11 K V Kamoth Additional Director
12 Richard Zahn Additional Director
13 K V Kamath Independent Director
14 Vijay Kelkar Independent Director
15 Richard Zahn Independent Director
INTRODUCTION OF LUPIN PHARMA
About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational

pharmaceutical company producing a wide range of quality, affordable generic
and branded formulations and APIs for the developed and developing markets of
the world. The Company today has significant market share in key markets in the
Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI,
Anti-Infectives and NSAIDs therapy segments, not to mention global leadership
positions in the Anti-TB and Cephalosporins. The Company’s R&D endeavors
have resulted in significant progress in its NCE program. The Company’s foray
into Advanced Drug Delivery Systems has resulted in the development of
platform technologies that are being used to develop value-added generic
pharmaceuticals.
Our Drugs and products reach over 70 countries in the world. Today, Lupin has
the unique distinction of being the fastest growing top 10 Generics players in the
two largest pharmaceutical markets of the world – The U.S (ranked 8th by
prescriptions & growing at 50 %) and Japan (ranked 7th and growing at 23%). The
company is also the fastest growing, top 5 pharmaceutical players in India (ORG
IMS - March 2009) and the fastest growing Generic player in South Africa (ranked
6th and growing at 36 % YoY - IMS)
For the financial year ended March 2009, Lupin's Consolidated Revenues and
Profit after Tax were Rs.39,145 million (US$ 851 million) and Rs. 5015 million (US$
109 million) respectively. Please visit http://www.lupinworld.com for more
information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Ltd.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated
to delivering high-quality, affordable generic medicines and branded formulations
trusted by healthcare professionals and patients across geographies. For more
information, visithttp://www.lupinpharmaceuticals.com.
Lupin Pharma
The Company’s concerted focus on the semi-acute therapy
is the crux of the Lupin division, which has enabled the
Company to attain market leadership in the Anti-TB segment
of IPM. In a Rs.3,162mn Anti-TB market, Lupin commands
48% of the market share. As market leaders in this space,
Lupin has embarked on an effort which would redefine the
treatment guidelines based on conditions existing in India
under the aegis of RIETT-Redefining Indian Expertise Based
Tuberculosis Treatment.

Key Products : LupinPharma

 Product Rank in the
Therapeutic relevant segment
Product
segment

R-Cinex Anti-TB 1
AKT Anti-TB 1
Akurit Anti-TB 1
R-CIN Anti-TB 1
G-CIN Gemifloxacin 1
Combutol Ethambutol& 1
Comb.
Pyzina Pyrazinamide 2
Plain

Market 52-Week
Sales(Rs.Million Current Change
Company P/E Ratio Cap. High/Low
) Price (%)
(Rs.Million)

Sun Pharma 38615.50 1546.05 0.03 29.99 320119.09 1846/1070

Cipla 49606.00 316.75 0.06 23.49 254164.76 363/211

Dr Reddy's 41589.00 1289.90 -1.59 26.16 221305.65 1335/598

Ranbaxy Labs. 47802.86 422.90 1.54 7.89 175208.31 538/217

Glaxosmithkline
18707.67 2038.00 -0.30 32.03 173149.91 2271/1086
Phar
Lupin 28985.60 1815.60 0.12 24.87 161393.89 1844/755

Cadila Healthcare 16985.00 612.00 2.84 24.21 121845.84 838/188

Piramal Healthcare 23162.60 500.65 -0.34 23.69 104997.75 600/250

Divi'S Lab 11905.60 721.00 4.42 34.04 91238.92 728/452

GlenmarkPharma 8545.59 271.45 3.84 44.79 70546.36 304/199

Biocon 9123.37 286.55 1.00 22.85 56740.00 311/164

Jubilant Life 24285.34 344.00 1.79 14.78 53659.62 373/155

AurobindoPharma 27948.30 882.60 2.66 10.01 48392.67 990/326

TorrentPh 11848.92 538.90 1.27 21.71 45025.94 555/164

Aventis Pharma 9744.06 1873.00 1.08 27.89 42675.74 1968/1030

Matrix Laboratories 15021.32 209.35 0.00 18.90 32729.53 227/165

Pfizer 8310.44 1050.00 0.14 22.30 31288.75 1125/711

Ipca Laboratories 12956.40 244.05 -1.09 17.19 30899.92 304/85

Ster.Biot 11783.81 112.00 0.81 16.16 27796.84 146/90

AstrazenecaPharm
3965.06 841.00 1.41 39.15 20732.50 1109/570
a

Fresenius
2620.83 129.05 3.16 53.38 19794.28 163/42
KabiOncol

SunPhaAdv 351.42 93.15 0.22 0.00 19251.47 105/57

Novartis 5994.80 611.15 3.22 16.32 18923.99 633/385

DishmanPharma 4158.85 221.90 0.29 21.25 17854.24 275/136

Wyeth 2863.60 785.00 1.16 29.88 17630.77 850/500

FDC 5763.62 91.50 1.95 13.60 16718.50 96/37

Strides Arcolab 7694.42 346.40 -3.27 16.57 15587.78 371/98

Abbott India 7945.57 1072.00 -2.27 19.83 15000.37 1210/415

Unichem Lab 6568.67 403.40 1.34 10.75 14357.19 453/189

Wockhardt 15038.91 121.10 0.67 0.00 13165.14 201/107

Solvay Pharma 2417.26 2519.95 3.81 28.12 12257.40 3600/650

PlethicoPharma 4721.43 351.70 0.03 15.41 11977.84 405/151

Panacea Biotec 7734.17 173.95 2.72 14.15 11319.82 248/100

Merck 4731.10 635.00 1.19 14.42 10416.94 687/371

Orchid Chemicals 11914.40 140.25 2.86 0.00 9604.78 239/78

Nectar Lifesciences 7279.68 37.85 0.00 10.70 8488.28 44/15

JB Chem&Pharma 6767.61 81.10 1.31 6.69 6753.75 96/37

Elder Pharma 6200.22 368.95 5.28 11.96 6608.61 408/218

Shilpa Medicare 1359.55 297.40 1.47 13.59 6455.28 363/64

Alembic 10940.85 47.05 1.62 29.89 6181.79 56/35

Indoco Remedies 3506.35 400.95 0.14 11.69 4919.60 442/148

NatcoPharma 2696.92 162.00 2.11 9.72 4465.67 184/71

Bliss GVS 1329.56 42.60 2.40 10.46 4290.90 51/15

Parenteral Drugs 2260.74 193.00 -2.03 14.25 3821.82 255/57

Zenotech Lab. 60.23 112.50 1.35 0.00 3821.65 139/93

Fulford India 1947.00 990.15 1.59 24.25 3801.14 1150/436

Morepen Labs 1641.04 7.90 2.33 0.00 3472.66 12/7

Ankur Drugs 9653.21 183.40 4.80 3.78 3384.78 251/100

Suven Life
1400.11 28.35 3.09 45.78 3204.75 37/18
Sciences

Piramal Life
21.30 130.50 4.99 0.00 3163.60 152/50
Science

Sequent Scientific 1060.62 139.95 0.14 26.57 3065.44 164/35

12800/251
Zandu Realty 877.46 3540.00 -0.65 8.66 2873.40
3

Shasun Chemicals 4708.34 58.50 2.45 22.60 2758.73 72/18

TTK Healthcare 2196.47 342.00 -2.56 29.87 2725.86 435/101

Surya Pharma 7229.24 172.85 3.01 3.25 2427.79 196/75

Alchemist 3864.66 185.00 0.57 13.26 2252.43 216/82

Twilight Litaka Phar 3704.43 107.25 3.08 6.63 2214.32 132/33

Venus Remedies 2640.94 266.50 3.11 4.83 2194.75 312/182

Ajanta Pharma 3194.77 183.30 2.75 7.32 2088.80 212/73

Themis Medicare 1998.98 245.80 3.47 10.58 1912.40 301/60

Granules India 2538.74 96.50 1.85 7.94 1900.42 115/52

Amrutanjan Health 906.60 613.00 0.14 14.23 1854.81 1345/324

IndSwiLab 5834.95 66.50 2.23 3.77 1811.80 80/34

Phaarmasia 111.00 253.00 -4.99 0.00 1727.22 344/253

SMS Pharma 2445.92 167.95 2.41 71.17 1642.49 190/109

MarksansPharma 1995.30 4.35 2.35 707.32 1563.18 8/4

Vivimed Labs 1514.89 156.75 1.59 12.96 1537.58 175/65

Jupiter Bioscience 1429.28 81.95 0.43 4.90 1510.29 105/52

Aarti Drugs 3765.03 112.25 3.08 5.62 1318.62 128/48

Anu's Labs 1597.09 5.90 8.66 7.67 1311.45 27/5

Kilitch Drugs 1290.12 100.00 3.31 10.84 1277.97 157/59

Sharon Bio-
4197.91 115.00 2.68 5.30 1182.37 144/42
Medicine

Kopran 1186.42 32.10 4.05 11.60 1144.62 37/9

IndSwiLtd 5870.55 29.50 1.03 3.03 1085.61 37/16

Wanbury 1672.88 72.45 1.26 0.00 1051.02 96/44

AnuhPharma 1205.13 377.85 2.29 7.97 1028.41 465/172

RPG Life Sciences 1392.43 70.80 5.12 9.40 1014.89 92/26

Bharat
71.08 18.75 3.02 0.00 785.88 26/17
Immunological

Ambal Sarabhai 625.10 10.12 1.30 4.14 765.57 17/10

Hester Biosciences 301.60 136.50 -0.73 12.14 713.79 156/76

Albert David 2056.92 124.05 1.39 6.80 698.27 143/62

Syncom Healthcare 605.65 39.20 1.29 17.07 677.25 162/39

BafnaPharma 457.99 43.60 3.20 14.19 675.21 45/19

Adinath Bio-Lab 218.18 2.86 -4.35 34.79 660.02 21/3

Lyka Labs 1520.75 29.25 2.63 26.45 615.03 41/17

DIL 17.68 263.00 5.05 7.50 574.10 309/146

JagsonpalPharma 1361.98 21.20 6.53 5.70 521.34 27/11

Neuland Lab. 3067.22 94.95 2.10 0.00 501.87 160/92

HiranOrgochem 1885.67 9.55 1.38 0.00 494.58 13/4

Kerala Ayurveda 179.85 45.35 0.00 0.00 478.70 66/30

Gufic Biosciences 515.76 6.13 3.03 36.13 460.23 11/4

Arvind Remedies 2178.88 1.73 5.49 5.75 426.48 3/1

Smruthi Organics 729.54 105.25 0.19 7.22 400.81 132/38

AhlconParenterals 378.30 54.25 0.00 9.19 390.61 58/22

Lincoln Pharma 1140.18 32.50 2.52 4.58 358.55 39/19

Celestial Biolabs 192.51 31.55 5.34 5.96 352.90 45/14

Rubra
10.21 61.85 4.92 0.00 322.36 59/10
Medicaments

Syncom
575.64 26.50 4.33 6.47 315.22 34/15
Formulations

Alpa Lab 1201.01 14.65 -0.68 38.94 310.35 20/11

Elder 508.08 74.35 -1.20 0.00 301.00 111/26

Maxter

As the face of Lupin in the critical care segment and Anti-

Infectives, Maxter Division emulates the Company’s
objective of ‘saving more lives’. As a spin-off from
Endeavour, the division was launched in 2006-07. The
inception of Maxter has empowered Lupin to tap unexplored
opportunities in chosen therapeutic area, with an
unwavering focus. This division focuses on giving the best
therapeutic care in the critical care segment. It reaches out
to interventionists and super-specialty doctors and has also
ventured into the field of wound management.

Key Products :Maxter

 Product Rank in the
Product Therapeutic segment relevant segment

Merotrol Meropenem 1
Tazar Piperacillin + 1
Tazobactam
Ceff Cephalexin Oral 3
Solids
Cetil Cefuroxime Oral 5
Solids
Cefantral CefotaximeInjectible 9
s

PRODUCTS OF LUPIN PHARMA

 LupinPharma

Brand Name Molecule Therapy Segment

Each Kit contains
AKT 2 RIFAMPICIN - 450 MG+ TUBERCULOSTATIC
ISONIAZID - 300 MG
Each Kit contains
RIFAMPICIN - 450 MG +
AKT3 TUBERCULOSTATIC
ISONIAZID - 300 MG+
ETHAMBUTOL - 800 MG
Each Kit contains
RIFAMPICIN - 450 MG +
ISONIAZID - 300 MG +
AKT4 TUBERCULOSTATIC
ETHAMBUTOL - 800 MG +
PYRAZINAMIDE - 1500
MG
Each tablet contains
RIFAMPICIN - 150
AKT FD MG+ISONIAZID -100 MG + TUBERCULOSTATIC
ETHAMBUTOL - 267 MG +
PYRAZINAMIDE - 500 MG
Each tablet contains
RIFAMPICIN - 150 MG +
ISONIAZID - 75 MG
AKURIT4 TUBERCULOSTATIC
+ETHAMBUTOL - 275 MG
+ PYRAZINAMIDE - 400
MG
Each tablet contains
RIFAMPICIN - 150 MG +
AKURIT3 TUBERCULOSTATIC
ISONIAZID - 75 MG +
ETHAMBUTOL -275 MG
Each tablet contains
AKURIT RIFAMPICIN - 150 MG + TUBERCULOSTATIC
ISONIAZID -75 MG
Each tablet contains
AKURIT Z RIFAMPICIN - 60 MG +
TUBERCULOSTATIC
KID ISONIAZID -30 MG +
PYRAZINAMIDE -150 MG
Each tablet contains
AKURIT KID RIFAMPICIN - 60 MG + TUBERCULOSTATIC
MindVision
Brand
Molecule Therapy Segment
Name
Stalopam Escitalopram 5mg Antidepressant

Escitalopram 10mg Antidepressant

Escitalopram 20mg Antidepressant

Escitalopram 10mg +
Stalopam Plus Antidepressant
Clonazepam 0.5mg

Citistar Citicoline 500mg Nootropic

Citicoline (250mg/ml) Nootropic

Citicoline 500mg
Nootropic
(250mg/ml)

Citicoline 1000 mg
Sustained Release Nootropic
tablets

Levetiracetam 250mg
Epilive Antiepileptics
Tablets

Levetiracetam 500mg
Antiepileptics
Tablets

Levetiracetam 750mg
Antiepileptics
Tablets

Lovax Oxcarbazepine 150mg Antiepileptics

Oxcarbazepine 300mg Antiepileptics

Oxcarbazepine 600mg Antiepileptics

Oxcarbazepine 300mg
Lovax OD Antiepileptics
Extended Release

Oxcarbazepine 600mg
Antiepileptics
Extended Release

Dayo OD Divalproex 250mg Antiepileptics

Divalproex 500mg Antiepileptics

Divalproex 750mg Antiepileptics

Pregadoc Pregabaline 75mg Agent for neurpathic pain

Pregabaline 150mg Agent for neurpathic pain

Pregabalin 75mg +
Pregadoc M Mecobalamin 750mcg Agent for Neuropathic Pain
Capsules

Pregabalin 150mg +
Mecobalamin 750mcg Agent for Neuropathic Pain
Pinnacle
For more details on the below given information, kindly
visit www.epinnacleworld.com

Brand Name Molecule Therapy Segment

TONACT 5 Atorvastatin Cholesterol Reducer

TONACT 10 Atorvastatin Cholesterol Reducer

TONACT 20 Atorvastatin Cholesterol Reducer

TONACT 40 Atorvastatin Cholesterol Reducer

TONACT 80 Atorvastatin Cholesterol Reducer

TONACT PLUS Atorvastatin + Niacin Cholesterol Reducer

TONACT FORTE Atorvastatin + Niacin Cholesterol Reducer

TONACT 10MG EZ Atorvastatin +Ezetimibe Cholesterol Reducer

TONACT 20mg EZ Atorvastatin +Ezetimibe Cholesterol Reducer

TONACT TG Atorvastatin + Fenofibrate Cholesterol Reducer

TONACT 10 MP Atorvastatin Cholesterol Reducer

Atorvastatin + Fenofibrate
TRITONACT Cholesterol Reducer
+ Ezetimibe

Cholesterol Reducer + Anti-

TONACT-TM Atorvastatin + Telmisartan
Hypertensive

RAMISTAR 1.25 Ramipril Anti-Hypertensive

RAMISTAR 2.5MG Ramipril Anti-Hypertensive

RAMISTAR 5MG Ramipril Anti-Hypertensive

RAMISTAR 10MG Ramipril Anti-Hypertensive

RAMISTAR A 2.5 Ramipril + Amlodipine Anti-Hypertensive

RAMISTAR H 2.5 Ramipril +Hctz Anti-Hypertensive

RAMISTAR H 5 Ramipril +Hctz Anti-Hypertensive

RETORLIX 5 Torsemide Diuretic

RETORLIX 10 Torsemide Diuretic

RETORLIX 20 Torsemide Diuretic

RETORLIX 100 Torsemide Diuretic

RETORLIX
Torsemide Diuretic
injection

Torsemide +
RETORLIX SP Diuretic
Spironolactone

VALENT 40 Valsartan Anti-Hypertensive

VALENT 80mg Valsartan Anti-Hypertensive

VALENT H Valsartan + Hctz Anti-Hypertensive

VALENT 160 Valsartan Anti-Hypertensive

VALENT R Valsartan +Ramipril Anti-Hypertensive

PINOM 10 Olmesartan Anti-Hypertensive

PINOM 20 Olmesartan Anti-Hypertensive

PINOM 40 MG Olmesartan Anti-Hypertensive

PINOM H Olmesartan + Hctz Anti-Hypertensive

PINOM A 20 MG Olmesartan + Amlodipine Anti-Hypertensive

CLOPITAB 75mg Clopidogrel Antiplatelet

CLOPITAB 150 Clopidogrel Antiplatelet

CLOPITAB A 75 Clopidogrel + Aspirin Antiplatelet

CLOPITAB A 150 Clopidogrel + Aspirin Antiplatelet

CILODOC 50 Cilostazol Antiplatelet

CILODOC 100 Cilostazol Antiplatelet

FAXIMAB 10MG/5
Abciximabinj Antiplatelet
ML VIAL

LUPENOX 20MG Enoxaparin Anticoagulant

LUPENOX 40MG Enoxaparin Anticoagulant

LUPENOX 60MG Enoxaparin Anticoagulant

PLANEP Eplerenone Diuretic

ISONORM 10 IsosordibeMononitrate Antianginal

ISONORM 20 IsosordibeMononitrate Antianginal

ISONORM 30 SR IsosordibeMononitrate Antianginal

IVABRAD 5MG Ivabradine Antianginal

IVABRAD 7.5MG Ivabradine Antianginal

DOFUSE Injection Dobutamine Positive Ionotropes

LUPIDIP 2.5/5/10
Amlodipine Anti-Hypertensive
mg

LUPIBOSE
Bosentan Pulmonary Anti-Hypertensive
62.5/125 mg

Resveratrol + Grape seed

HARTY Nutritional Supplement
extract
 Pinnacle CVN (CARDIOVASCULAR
NEPHROLOGY)
Brand Name Molecule Therapy Segment
ATENOVA 25
Atenolol Anti-Hypertensive
MG
ATENOVA 50
Atenolol Anti-Hypertensive
MG
ATENOVA 100
Atenolol Anti-Hypertensive
MG
EZEDOC Ezetimibe Cholesterol Reducer
Frusemide +
FRUSELAC Diuretic
Spironolactone
Frusemide +
FRUSELAC DS Diuretic
Spironolactone
IsosordibeMonon
ISONORM 10 Anti-Anginal
itrate
IsosordibeMonon
ISONORM 20 Anti-Anginal
itrate
IsosordibeMonon
ISONORM 30 SR Anti-Anginal
itrate
LIPRIL 2.5mg Lisinopril Anti-Hypertensive
LIPRIL 5mg Lisinopril Anti-Hypertensive
LIPRIL 10mg Lisinopril Anti-Hypertensive
Lisinopril +
LIPRIL AM Anti-Hypertensive
Amlodipine
Lisinorpil +
LIPRIL H Hydrochlorothiazi Anti-Hypertensive
de
NEBISTAR
Nebivolol Anti-Hypertensive
2.5mg
NEBISTAR 5mg Nebivolol Anti-Hypertensive
Nebivilol + s-
NEBISTAR SA Anti-Hypertensive
amlodipine
Nebivilol +
NEBISTAR H Hydrochlorothiazi Anti-Hypertensive
de
STARPRESS XL
Metoprolol Anti-Hypertensive
100
STARPRESS XL
Metoprolol Anti-Hypertensive
25
STARPRESS XL
Metoprolol Anti-Hypertensive
50
Metoprolol +
STARPRESS H
Hydrochlorothiazi Anti-Hypertensive
25 XL
de
Metoprolol +
STARPRESS H
Hydrochlorothiazi Anti-Hypertensive
50 XL
de
STARPRESS Metoprolol +
Anti-Hypertensive
AM XL 30 Amlodipine
STARPRESS Metoprolol +
Anti-Hypertensive
AM XL Amlodipine
Metolprolol +
STARPRESS
Isosorbidemonon Anti-Hypertensive+Anti-Anginal
MN XL 30
itrate
Metolprolol +
STARPRESS
Isosorbidemonon Anti-Hypertensive+Anti-Anginal
MN XL 60
itrate
STARPRESS R Metoprolol +
Anti-Hypertensive
XL 25 Ramipril
STARPRESS R Metoprolol +
Anti-Hypertensive
XL 50 Ramipril
RANCAD Ranolazine Anti-Anginal
NOVASTAT
Rosuvastatin Cholesterol Reducer
5MG
NOVASTAT
Rosuvastatin Cholesterol Reducer
10MG
NOVASTAT
Rosuvastatin Cholesterol Reducer
20MG
FLETA BOLUS
Eptifibatide Antiplatelet
INJ
FLETA
Eptifibatide Antiplatelet
INFUSION
TIROFUSE Tirofiban Antiplatelet
Recombinant
LUPIFLO 7.5 L Fibrinolytic
Streptokinase
Recombinant
LUPIFLO 15 L Fibrinolytic
Streptokinase
SENACEPT Cinacalcet HCL Calcimimetic

Endeavour
Brand Name Molecule Therapy Segment
CALCIUM CARBONATE +
CALUFT CAPS CALCITRIOL + ZINC + ANTI-OSTEOPOROSIS
MAGNESIUM + BORON
CALCIUM CITRATE
MALEATE + VIT.D3 + ZINC +
CALUFT-G CALCIUM PREPARATION
MANGANESE + MAGNESIUM
+ COPPER
CEFAXONE 100
CEFTRIAXONE IM/IV ANTI INFECTIVE INJECTABLE
0 Mg
CEFAXONE 125
CEFTRIAXONE IM/IV ANTI INFECTIVE INJECTABLE
Mg
CEFAXONE 250
CEFTRIAXONE IM/IV ANTI INFECTIVE INJECTABLE
Mg
CEFAXONE 500
CEFTRIAXONE IM/IV ANTI INFECTIVE INJECTABLE
Mg
Anti-bacterial
CEFFOREN CEFDITOREN
(CEPHALOSPORIN ORAL)
CO-Q-DENT CO-Q-10 HERBAL TOOTHPASTE
CO-Q-DENT CO-Q-10 HERBAL TOOTHPASTE
PHENYLPROPANOLAMINE
CZ-3 COLD 25MG + CETIRIZINE 5MG + COLD PREPARATION
PARACETAMOL 500MG
CZ-3 SYRUP CETRIZINE ANTI-HISTAMINE
CZ-3 TABLET CETRIZINE ANTI-HISTAMINE
CETRIZINE 5MG +
CZ-COLD PSEUDOEPHEDRINE COLD PREPARATION
30MG/5ML
AMBROXOL 15MG + R-
SALBUTAMOL 1MG +
CZ-EX COUGH PREPARATION
GUAIPHENESIN 50 MG +
MENTHOL 0.5MG
DEXTROMETHORPHAN +
CETRIZINE +
CZ-TUS COUGH PREPARATION
PSEUDOEPHEDRINE +
MENTHOL
Anti-bacterial
DOXCEF 100 CEFPODOXIME
Lupin Diabetes Care
Brand Name Molecule Therapy segment
Metformin 500 mg
Gluconorm SR Diabetes Management
extended release
Gluconorm SR Metformin 1 gm extended
Diabetes Management
1g release
Metformin 500 mg ER +
Gluconorm G1 Diabetes Management
Glimepiride 1 mg
Metformin 500 mg ER +
Gluconorm G2 Diabetes Management
Glimepiride 2 mg
Metformin 500 mg ER +
Gluconorm P15 Diabetes Management
Pioglitazone 15 mg
Metformin 500 mg ER +
Gluconorm P30 Diabetes Management
Pioglitazone 30mg
Metformin 500 mg ER +
Gluconorm PG-
Pioglitazone 15 mg + Diabetes Management
1
Glimepiride 1 mg
Metformin 500 mg ER +
Gluconorm PG-
Pioglitazone 15 mg + Diabetes Management
2
Glimepiride 2 mg
Gluconorm G1 Metformin 1 gm ER +
Diabetes Management
Forte Glimepiride 1mg
Gluconorm G2- Metformin 1 gm ER +
Diabetes Management
1 Forte Glimepiride 2 mg
Glutide CR Gliclazide Controlled
Diabetes Management
30MG Release 30 mg
Glutide CR Gliclazide Controlled
Diabetes Management
60MG Release 60 mg
Glador 1 Glimepiride 1 mg Diabetes Management
Glador 2 Glimepiride 2 mg Diabetes Management
Glador 3 Glimepiride 3 mg Diabetes Management
Glador 4 Glimepiride 4 mg Diabetes Management
Lipril 2.5 Lisinopril 2.5 mg Diabetic Hypertension
Lipril 5 Lisinopril 5 mg Diabetic Hypertension
Lipril 10 Lisinopril 10 mg Diabetic Hypertension
Lisinopril 5 mg +
Lipril AM Diabetic Hypertension
Amlodipine 5 mg
Lisinopril 5 mg +
MARKET SHARE OF LUPIN PHRMA

Lupin Q4 & FY 2008-09 Results -

Consistent Performance & Solid
Growth
Q4 2008-09 Consolidated Net Profits up 64.2% at Rs.
1574 million

May 13, 2009, Mumbai, India

Leading transnational pharmaceutical major, Lupin Limited,
reported an outstanding performance for the fourth quarter
and financial year ended March 31st, 2009. These audited
results were taken on record by the Board of Directors at a
meeting held in Mumbai today.
Key Highlights - Consolidated FY 08-09
• Net sales grew at 39.5% to Rs. 37759 million from Rs.
27064 million
• last year
 • Net profit grew at 50.2% to Rs. 5015 million compared
to Rs. 3338 mn in previous year (excluding IP income)
• EBITDA margin increased to 19.7%
• Exports up by 63.2% at Rs. 24701 mn
• Advanced markets sales (including Japan and ANZ)
increased to 92% over last year and contributed 50% of
the Net Sales for the year as against 36% in the
previous year.
• Advanced Markets sales to US and EU grew at 70% to
Rs.14310 million including API
• One of the fastest growing generic players in the US by
prescriptions and the 9th largest in terms of total
prescription base
• A basket of 22 products in the US with 8 market leaders
• Domestic Formulations Business grew at 24.6%% to
Rs. 10,575 million.
• Lupin’s Japanese subsidiary, Kyowa contributed 12%
of the overall revenues - Rs. 4424 million
• 28 ANDAs, 15 DMFs, 18 MAAs,6 EDMFs,3 COS, & 1 AU
DMF were filed during FY 08-09.
• Four Major Acquisitions across Germany, Australia,
South Africa and the Philippines
• Dividend Announcement of 125 %
Key Highlights Q4 FY 08-09
• Net sales for Q4 FY 08-09 grew at 39% to Rs.10434
million.
• Advanced markets sales (U.S, EU & Japan) increased
to 86 % at Rs 5681 million over Q4 FY 07-08
• Net profit for Q4 FY 08-09 grew at 64.2% to Rs.1574
million compared to Rs. 959 million in Q4 FY 07-08
Commenting on Lupin’s performance, Dr. Kamal K Sharma,
Managing Director, Lupin Limited, said, “Lupin’s stellar
performance reflects the strong business philosophy
guiding us. Lupin has had a very strong year driven by
growth and consistent performance across all business
segments and markets: a strong business performance in
the US, solid domestic growth & increased activity in all key
markets. Lupin’s acquisitions have not only consolidated
our existing presence in these markets but also leaves us
strategically poised to further strengthening our position in
the global generics and branded generics market. It has
indeed been a year of many achievements and robust
growth, and we are now strategically poised to not only
address market needs but also maintain momentum and
direction.”

Financials:
Advanced markets – US & Europe
Lupin continued its growth momentum in the US and Europe
a healthy contribution of 36% to our total revenues at Rs.
13634 million. (Formulations)
USA:
Lupin Pharmaceuticals Inc., the company’s US subsidiary,
reported a stellar performance recording sales of Rs. 12563
million reflecting a growth of 74.4% as compared to Rs. 7205
million in FY 07-08. Lupin’s Generic and Branded business
recorded exponential growth during the financial year.
More importantly, FY 08-09 saw Lupin increasing its product
portfolio in the branded generics segment through the
launch of AeroChamber Plus®. LPI forged a Strategic
Alliance with Forest Laboratories, Inc. for marketing and
promoting AeroChamber Plus® thereby extending Lupin’s
presence in the respiratory segment and our franchise with
Pediatricians which would also additionally open up new
offices for Suprax. The brand business contributed 27% to
the overall business at USD 74 mn
The company further expanded and consolidated on its
generic product portfolio with the launches of Ramipril caps,
Divalproex DR tabs, Cefadroxil suspension and caps
&Levetiracetam tabs. The Company now has a total of 22
products in the market, out of which 8 are market leaders.
We are in the top 3 market positions by market share in 17 of
these products (IMS Jan 09).
Lupin today is one of the fastest growing generic players in
the US based on growth in prescriptions and the 9th largest
in terms of total prescription base.
LPI was also recognized by Wal-Mart and awarded its
prestigious “Supplier Award of Excellence” for the 2nd
Quarter 2008 – which is an acknowledgement of the inroads
we have made into the US markets.
During the year, the company demonstrated its capabilities
on the Intellectual Property management front by
successfully litigating and settling all ongoing Hatch-
Waxman litigation relating to Desloratadine tablets, the
generic version of Schering-Plough’s "Clarinex"® tablets. As
per the terms of the settlement, Lupin Ltd. will be licensed
under the relevant Desloratadine patents, and free to
commercially launch its generic Desloratadine product, on
July 1, 2012, or earlier in certain circumstances. Schering-
Plough’s Clarinex® tablets had U.S. sales of $329 million for
the year 2007-MAT June 2008, according to IMS Health.
Lupin also received the final approval for the Company’s
Abbreviated New Drug Application (ANDA) for Levetiracetam
Tablets 250mg, 500mg, 750 mg and 1000 mg from the U.S.
Food and Drug Administration (USFDA). Commercial
shipments of the product have commenced.
Lupin’sLevetiracetam tablets are the AB-rated generic
equivalent of UCB Pharmaceuticals’ Keppra® tablets,
indicated as adjunctive therapy in the treatment of certain
types of seizures associated with epilepsy. Keppra tablets
had annual sales of approximately $ 1.2 billion (USD) for the
twelve months ended September 2008, based on IMS Health
sales data.
Europe:
Lupin further strengthened its presence in the European
Union by completeing its acquisition of HormosanPharma
GmbH (Hormosan), a German generics company specialized
in the supply of pharmaceutical products for the Central
Nervous System (CNS).
We also recorded our first strategic win in the German
market through Hormosan in the next two quarters – having
received information on the results of the
AllgemeineOrtskrankenkassen (AOK) Tender, pursuant to §
130a SGB V. Hormosan has been offered to supply Setraline
in all 5 regions of Germany covering all AOK-insured
persons.
Hormosan has a strong brand identity in the German
generics market through its strong patient compliance
message, essential for patients within the CNS sector.
Lupin also made strategic inroads into the French market by
launching CefpodoximeProxetil suspension in Q3.
CefpodoximeProxetil has over 60 % market share in France.
AAMLA
Japan:
Kyowa, the Company’s subsidiary in Japan posted robust
net sales of Rs. 4424 mn contributing 12% of Lupin’s
Revenues having grown at over 21 % YoY
Our products like Amlodipine “Amel” continues to maintain
majority market share and Risperidone “Amel”, which was
launched last year, continue to exhibit market leadership in
unit terms.
South Africa
Lupin clocked in revenues of Rs 919 million after having
acquired an equity stake in Pharma Dynamics (PD) in South
Africa in September 08. Pharma Dynamics is one of the
fastest growing generic companies in South Africa growing
at around 30 % for FY 08-09 with a clear leadership in the
cardiovascular segment.
PD is ranked number 6 amongst generic companies in South
Africa. The South African Generics Market is currently
valued at close to 800 Million USD and growing rapidly
Phillipines
In March 2009 the Company acquired a majority stake in
MulticarePharmaceuticals Phillipines, Inc. (MC) in
Phillipines. MC is a premium branded generics company
with a strong position in women’s health and child care
segment.
ANZ
The Company continued its focus on this important market
with aggressive filings in Australia, taking the cumulative
MAA filings to 24 till date of which 18 have been approved.
Emerging Markets
India
Domestic Formulations forms a very important part of
Lupin’s overall growth. In the current financial year, it
contributed about 28% of the net sales at Rs 10,575 million
as against Rs. 8,487 million registering a growth of 24.6%
over the previous year.
This growth was driven by the good performance in the CVS,
Diabetes, CNS, Asthma and Gastro therapy Segments. The
divisions catering to branded segments continued to
outpace the industry growing over 27%. Lupin has
maintained its leadership in Anti-TB segment and has
secured a double digit market share in the anti-asthma
market riding high on the strengths of its offering in this
segment.
Research and Development
Research & Development has always been a strategic and
 key focus area for Lupin and this year – 2008-09 was no
exception with 6% of the sales earmarked for R&D and
related spends.
The year 2008-09 was a landmark year with Lupin filing 28
Abbreviated New Drug Application (ANDA) with the USFDA,
11 DMFs, 15 MAAs and two EDMFs during the year.
The cumulative ANDA filings stood at 90 with 34 approvals
granted by the USFDA.
Lupin also received the final approval for the Company’s
Abbreviated New Drug Application (ANDA) for Levetiracetam
Tablets 250mg, 500mg, 750 mg and 1000 mg from the U.S.
Food and Drug Administration (USFDA) during the quarter.
Other
The USFDA issued a warning letter for the Cephalosporin
facility of the Mandideep plant. The facility was inspected in
November, 2008 for a routine GMP inspection. As a result
Lupin had received 15 procedural observations. Lupin
responded to the observations in December and provided
corrective actions for each of the responses.
The warning letter was issued to provide Lupin with an
opportunity to submit additional documentation and
explanation to a few selected observations where the FDA
felt that the initial responses were inadequate and could be
strengthened by further evidence of compliance with
enhanced documentation practices.
All products maintain their approved status. Lupin
manufacturing will not be disrupted and it will continue to
provide quality products to customers without interruption.
Lupin has formulated a strategy to address and resolve the
USFDA and is confident of being able to satisfy the USFDA’s
observations expeditiously.
Dividend-In view of excellent performance, the Board of
Directors recommended a dividend of 125 % i.eRs. 12.50 per
equity share of the face value of Rs. 10 each.

COMPANY MANUFACTURING/R&D
Business Development
Top of Form
Lupin was founded to meet the very basic need for effective treatment
of tuberculosis. Our success is tied to continually meeting the need
for basic products to promote human health. Our company strives to
bring important new products to market each year. We expect our
products to come from:
• In-house product development;
• Licensing and acquisitions;
• Marketing alliances.
Lupin is also seeking to be the partner of choice for product
development. Our scientists apply know how and expertise to
develop NCE’s or to solve difficult formulation challenges.
We strive for continued growth and are avidly interested in learning
about prospective opportunities in the specialty pharmaceutical
market. We are also open to collaborating to develop innovative
products formulated with Lupin’s drug delivery and taste masking
technology. Our API business unit is seeking partners for Lupin
developed API's.
Please contact us regarding business or product collaboration
opportunities
Phone: 410-576-2000
Facsimile: 410-576-2221
Email: admin@lupinusa.com

NEW Products
 Generics
Lupin Pharmaceuticals, Inc. entered the U.S.
generic pharmaceutical market in 2003 with the
ANDA approval for cefuroxime axetil. Since then we
have received more than a dozen FDA approvals.
Six of Lupin's 14 ANDA approvals were the first
granted by the US FDA, reinforcing our ability to
submit high quality dossiers and gain on time
approvals.
We are vertically integrated, from process
development of the API to the submission of
dossiers for finished dosages. This provides
control over the supply chain and the ability to
offer quality products at the right time and at
competitive prices.
Our integrated manufacturing capability provides a
portfolio of the highest quality generic products.
Expanding the product portfolio, Lupin
Pharmaceuticals, Inc. is geared to file 15 or more
ANDA’s per year in some of the following areas:
Oral and injectable cephalosporins;
Cardiovascular;
Controlled release ANDA’s;
Paragraph IV’s.
Our oral and injectable cephalosporin facilities, US
FDA approved manufacturing sites and the new
tablet and capsule facility in Goa, allow us to file
and manufacture a wide range of finished products
for the US market.

Newsroom

Lupin receives FDA approval for Imipramine Pamoate Apr 16, 2010
Capsules
View

Lupin receives FDA tentative approval for Eszopiclone Mar 20, 2010
tablets
View

Lupin receives FDA approval for Amlodipine/Benazepril Feb 08, 2010

capsules
View

Lupin receives FDA approval for Perindopril Erbumine Jan 28, 2010
Tablets
View

Lupin receives FDA tentative approval for Jan 19, 2010

MemantineHCl tablets
View

Lupin is granted USFDA approval for Levetiracetam Jan 16, 2009

Tablets
View

Lupin Receives “Supplier Award of Excellence” from Sept 17,

Wal-Mart 2008
View
Lupin receives USFDA approval for Divalproex Sodium July 29, 2008
Delayed-Release Tablets
View

Lupin appoints New NCE Research Head. June 26,

View 2008

Lupin Enters Into Marketing Alliance with ASCEND June 23,

Therapeutics for SUPRAX® 400 mg Tablets in the U.S. 2008
View

Lupin receives USFDA approval for Escitalopram June 16,

Oxalate Tablets 2008
View

Lupin launches Ramipril capsules June 10,

View 2008

Lupin receives USFDA approval for Topiramate Tablets May 29, 2008
View

Lupin Receives “Best New Manufacturer of the Year” July 30, 2007
Award from AmerisourceBergen
View

Lupin receives final approval for Amlodipine Tablets July 12, 2007
 View

Lupin announces Final Approval of Trandolapril Tablets June 13,

View 2007

Lupin Receives US FDA Approval for ZiprasidoneHCl May 22, 2007

Capsules
View

Lupin Announces Final FDA Approval of Cefdinir for May 8, 2007

Oral
Suspension, 250 mg/5 mL, Launches Entire Product
Family.
View

Lupin Receives US FDA Approval for Novel Formulation April 12,

of Suprax® Suspension 2007
View

Lupin Receives US FDA Approval for Sertraline. February 7,

View 2007

Products
Specialty
A commitment To Caring For Kids

Lupin Pharmaceuticals, Inc. is committed to developing a branded

pharmaceutical presence for pediatric practice in the US market. We
are committed to identifying, developing and marketing prescription
drugs for children of all ages. Lupin has created a dedicated national
sales force to call upon pediatricians.
Lupin Pharmaceuticals, Inc., is very pleased to offer Suprax®, an
important anti-infective product in pediatric and other physician
practices within the United States. Suprax® is now available in tablets
and suspension formulations. Lupin Pharmaceuticals, Inc., has an
exclusive license in the United States to use the Suprax® trademark.
We plan to expand our family of pediatric products to help meet
needs of children. Our focus is on in-house product development with
our proprietary oral controlled release and taste masking platforms.
Lupin Pharmaceuticals, Inc. is also open to marketing alliances, and
to licensing/acquisitions.

API
Lupin is recognized as a leading manufacturer of
cephalosporin API’s, with FDA approval to manufacture
complex oral and injectable cephalosporins.
Lupin is fast gaining share in the cardiovascular segment
manufacturing a wide range of ACE-inhibitors and
cholesterol reducing agents.
Lupin’s capabilities in sterile processing, synthetic
process development and fermentation skills coupled with
its intellectual property strengths, puts the company in a
very strong position to offer a diverse portfolio of niche
API’s to its customers.

SHARE IN MARKET ANNUL

Lupin Limited (NSE:EQLUPIN)

Lupin Limited is amongst the top six pharmaceutical companies
in India in terms of revenue. The Company is the world’s
largest manufacturer of Tuberculosis drugs.
Business Overview

Headquartered in Mumbai, India Lupin Limited is a

transnational pharmaceutical company producing generic and
branded formulations and Active Pharmaceutical
Ingredients(APIs)[1]The Company has secured global
leadership position in Anti-TB and Cephalosporins and has a
significant presence in the areas of Cardiovasculars (prils and
statins), Diabetology, Asthma and NSAIDs(Non-steroidal anti-
inflammatory drugs)[1]

Net profit for Q4 FY 08-09 grew at 64.2% at Rs. 1574 million

compared to Rs 959 million in Q4 FY 07-08.Net sales growth
for Q4 FY 08-09 was 39% at Rs. 10434 million. [1]

Business and Financial Metrics

Lupin Limited's share holding pattern
[4]
Entity Percentage
Indian Promoters 50.62%
Foreign Promoters 0.01%
FII's 11.15%
General Public9.21%Banks Fin. Inst. and
Insurance09.76%Private Corporate
Bodies1.48%NRI's/OCB's/Foreign
Others2.90%Others0.13%

Business Segments

Formulations Active Pharamceutical Ingredients and

Intermediates ROCE is comparable to the best in the segment
at 33%[6]

\
 in India and a presence in more than 100 countries. [12]In India it the biggest drug maker by

sales[13]

Comparison with the competitors:

Financial metrics FY2008

Sales
Yr Market
Turnove
Name Ende Capitalization Net Profit in Rs Cr
r in Rs
d in Rs Cr
Cr

Mar
Lupin 6,473.42 2,661.62 443.38
'08

Mar
Sun Pharma 26,975.87 2,427.35 1,014.04
'08

Mar
Cipla 17,947.66 4,293.95 701.43
'08

GlaxoSmith Dec
9,992.41 1,762.64 576.57
Kline '07

DrReddys Mar
9,662.53 3,428.40 475.22
Labs '08

Market Share on the basis of Retail Sales Due to high level of fragmentation none of the Pharma

Companies had more than 6% of the total market on the basis of the total retail sales.[15]